Evommune (EVMN) Research & Development (2024 - 2026)

Evommune (EVMN) has 3 years of Research & Development data on file, last reported at $17.3 million in Q1 2026.

• Research & Development for Q1 2026 came in at $17.3 million, up 20.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $71.7 million (changed N/A YoY), and the FY2025 annual result was $74.0 million, up 15.25% from the prior year.
• Research & Development slipped to $17.3 million in Q1 2026 per EVMN's latest filing, from $20.4 million in the prior quarter.
• Over five years, Research & Development peaked at $20.4 million in Q4 2025 and troughed at $13.3 million in Q3 2024.
• A 3-year average of $17.1 million and a median of $17.6 million in 2024 frame the typical range for Research & Development.
• On a YoY basis, Research & Development climbed as much as 47.78% in 2025 and fell as far as 14.42% in 2025.
• A 3-year view of Research & Development shows it stood at $17.8 million in 2024, then gained by 14.42% to $20.4 million in 2025, then dropped by 15.12% to $17.3 million in 2026.
• Business Quant data shows EVMN's Research & Development at $17.3 million in Q1 2026, $20.4 million in Q4 2025, and $19.6 million in Q3 2025.